

IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21^{WAF1} and IRF-1

Su-Jin Yu^{1,2,3}, Hyeon Soo Kim^{1,2,3},
Sung-Won Cho⁴ and Jeongwon Sohn^{1,2,3,5}

¹Department of Biochemistry
College of Medicine

²Graduate School of Biotechnology

³Korea Nutrition Research Institute

⁴Department of Parasitology

College of Medicine, Korea University

Seoul 136-705, Korea

⁵Corresponding author: Tel, 82-2-920-6192;

Fax, 82-2-922-6702; E-mail, biojs@korea.ac.kr

Accepted 3 August 2004

Abbreviations: CDK, cyclin dependent kinase; IRF-1, interferon regulatory factor-1; RCC, renal cell carcinoma

Abstract

Interleukin (IL)-4 inhibits proliferation of several human cancer cell lines *in vitro*. Although IL-4 is known to regulate proliferation of lymphocytes by modulating p27^{KIP1} expression, the mechanism involved in the IL-4-induced growth inhibition of nonhematopoietic cancer cells has not been fully elucidated. Previously, we reported that IL-4 suppressed proliferation of human renal cell carcinoma (RCC) cell lines *in vitro*. Here, we show that IL-4 inhibits cell cycle progression at the G₁ phase in Caki-1 cells by increasing the expression of p21^{WAF1} and interferon regulatory factor (IRF)-1, and decreasing the cyclin dependent kinase (CDK) 2 activity. Up-regulation of p21^{WAF1} and IRF-1 expression is transcriptional, but independent of p53. The levels of p21^{WAF1} and IRF-1 proteins were enhanced as early as 1 h after IL-4 treatment. CDK2 activity started to decline at 4 h after IL-4 treatment, and by 24 h, was ~50% of the control. Neither the protein expressions of p27^{KIP1} and p16^{INK4a}, nor the phosphorylation level of pRb was changed. The importance of p21^{WAF1} and IRF-1 in the growth inhibition induced by IL-4 was confirmed by antisense oligonucleotide transfection. Both of p21^{WAF1} and IRF-1 antisense oligonucleotides prevented IL-4-mediated growth

inhibition by ~30% compared to the respective sense oligonucleotides. In summary, our study indicated that p21^{WAF1} and IRF-1 mediate the growth inhibitory effect of IL-4 in human RCC cells.

Keywords: IL-4; interferon regulatory factor-1; p21^{WAF1}; renal cell carcinoma

Introduction

IL-4, originally found as a B cell growth factor, possesses pleiotropic effects including Th2 cell differentiation, and class switching to IgE and IgG1. IL-4 is produced by a subset of CD4 T cells, basophils and mast cells, and plays a central role in regulating differentiation and growth of lymphocytes (Brown and Hural, 1997). In early 1990s, IL-4 was shown to inhibit the growth of several cancers *in vivo* and the potential role of IL-4 in cancer therapy had been suggested (Tepper *et al.*, 1989; Golumbek *et al.*, 1991). The major mechanism by which IL-4 manifests its *in vivo* antitumor activity seems to be infiltration of inflammatory cells such as macrophages, eosinophils and neutrophils (Tepper *et al.*, 1991; Noffz *et al.*, 1998). However, it is also demonstrated that IL-4 can directly modulate proliferation of cancer cells of different types, including breast, gastric and renal cancers (Obiri *et al.*, 1993; Morisaki *et al.*, 1994; Cheon *et al.*, 1996; Gooch *et al.*, 1998). The molecular mechanism of the direct growth inhibitory effect of IL-4 has not been extensively studied.

p21^{WAF1/CIP1} is a member of the CIP/KIP family inhibitor of cyclin dependent kinases (CDKs) with a broad specificity. It can arrest cell cycle progression at both G₁ and G₂ phases (Deng *et al.*, 1995; Medema *et al.*, 1998). p21^{WAF1} is transcriptionally induced by both p53-dependent and -independent pathways (Rao *et al.*, 1998). Whereas up-regulation of p21^{WAF1} in response to a genotoxic stress is mediated by p53, cellular accumulation of p21^{WAF1} upon TGF- β stimulation or during cellular differentiation and senescence is independent of p53 (Datto *et al.*, 1995; Gartel *et al.*, 1999; Eum *et al.*, 2003). In both cases, the increase of p21^{WAF1} correlates with growth arrest, suggesting that it may be the common mediator for different growth inhibitory signals.

IRF (interferon regulatory factor)-1 is a member of

the IRF family transcription factors with a tumor suppressor activity. It regulates cell cycle progression, apoptosis, and DNA repair. The IRF-1 gene is frequently deleted in human leukemia, and inactivation of IRF-1 accelerates cell transformation (Willman *et al.*, 1993; Tanaka *et al.*, 1994). However, the mechanism by which IRF-1 exerts its tumor suppressor activity is not well understood. The target genes of IRF-1 such as PKR, Stat1, lysyl oxidase, and p21^{WAF1} may be responsible for its anti-oncogenic effect. In addition, IRF-1 reduces the promoter activation of CDK2 by interfering the activity of SP-1 (Xie *et al.*, 2003).

In the present study, we investigated the mechanism of IL-4-induced growth inhibition in RCC cells, and demonstrated that IL-4 increased the expression of p21^{WAF1} and IRF-1 transcriptionally to induce growth suppression. p27^{KIP1}, p16^{INK4a}, and pRb were not involved in the IL-4-mediated growth inhibition in RCC cells.

Materials and Methods

Cell lines and culture

Caki-1 and A498 are established human RCC cell lines, and obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea). Cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 µg/ml).

Antibodies

Antibodies against p21^{WAF1} (C-19), p27^{KIP1} (C-19), IRF-1 (C-20), and β-actin (I-19) were purchased from Santacruz, and anti-p53 (DO-1) antibody was purchased from Oncogene.

Cell cycle analysis

Cells were incubated with human recombinant IL-4 (Biosource International, Camarillo, CA), and analyzed for the cell cycle distribution as described previously (Sohn *et al.*, 1998). Briefly, cells were fixed in 70% ethanol overnight at -20°C, washed with phosphate buffered saline (PBS), and suspended in PBS containing 200 µg/ml RNase A and 20 µg/ml propidium iodide. After incubating for 30 min in dark, the cellular DNA content was analyzed by flow cytometry. Cell cycle was analyzed using a Cell Quest program (Beckton Dickinson, Mountain View, CA).

Immunoblot analysis

Cells were lysed in the extraction buffer (31.75 mM

Tris-HCl, pH 6.8 1% sodium dodecyl sulfate (SDS), 10% glycerol, and 2.5% β-mercaptoethanol), and the whole cell lysates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). The size-fractionated proteins on the gel were transferred onto a nitrocellulose membrane. The membrane was blocked in 5% skim milk in Tris-buffered saline containing 0.05% Tween 20, and incubated with a primary antibody. After washing, the membrane was incubated with the peroxidase-conjugated secondary antibody. The protein band of interest was detected using the enhanced chemiluminescence (ECL) reagents (Amersham, Arlington Heights, IL).

Reverse transcription-polymerase chain reaction (RT-PCR)

Total cellular RNA was extracted using the acid guanidinium isothiocyanate method (Chomczynski and Sacchi, 1987). cDNA was synthesized from the total cellular RNA using oligo (dT) primer (Promega, Madison, WI) and Moloney murine leukemia virus-reverse transcriptase (MMLV-RT) (Gibco BRL, Grand Island, NY). The cDNA served as a template for PCR amplification of p21^{WAF1} and IRF-1 genes. The sequences of PCR primers were as follows: p21^{WAF1}, 5'-CGAAGTCAGTTCCTTGTTGGA-3' and 5'-GGCAGAAGATGTAGAGCGGG-3'; IRF-1, 5'-AAGCATGCTGC CAAGCATGGCTGG-3' and 5'-ATCAGGCAGAGTGG AGCTGCT-3'. Thirty PCR cycles, each composed of 30 s denaturation at 95°C, 30 s annealing at 58°C, and 1.5 min extension at 72°C were carried. PCR products were analyzed by agarose gel electrophoresis.

in vitro CDK2 activity assay

Cell lysates containing 1 mg of protein were incubated overnight with an anti-CDK2 antibody (Transduction Laboratories, Lexington, KY) at 4°C, and protein A-Sepharose 4B (30 µl) (Pharmacia Biotech., Uppsala, Sweden) was added to the lysates. After incubating for 1 h, the mixture was centrifuged, and the pellet containing CDK2 was washed sequentially with a NP40 lysis buffer (150 mM NaCl, 1.0% NP40, 50 mM Tris, pH 8.0), and with a kinase assay buffer (50 mM HEPES-NaOH, pH 7.3, 10 mM MgCl₂, 5 mM MnCl₂, and 1 mM dithiothreitol). The pellet was resuspended in the kinase assay buffer (20 µl) containing 2.5 µg histone H1 and 5 µCi γ-³²PATP. The kinase reaction was carried out for 20 min at room temperature and was terminated by adding an equal volume of the 2×SDS sample buffer and boiling. Phosphorylation of the histone H1 was analyzed by SDS-PAGE and autoradiography.

Transfection of the p21^{WAF1} and IRF-1 antisense oligonucleotides

Phosphorothioate oligonucleotides were synthesized by Scandinavian Gene Synthesis AB (Koping, Sweden). The antisense and sense oligonucleotide sequences of p21^{WAF1} and IRF-1 are as follows: 5'-TCCCCA GCCGTTCTGACAT-3' (p21 antisense); 5'-ATGTCA GAACCGGCTGGGA-3' (p21 sense); 5'-GAAAGA TGCCCGAGATGC-3' (IRF-1 antisense); 5'-GCATCT CGGGCATCTTTC-3' (IRF-1 sense). Two hours after seeding, cells were transfected with antisense or sense oligonucleotides using LipofectinTM (GibcoBRL, Grand Island, NY), according to the manufacturer's instruction.

Proliferation assay

Cells plated on a 96-well microtiter plate were transfected with the p21^{WAF1} antisense or sense oligonucleotide. After incubating for 4 h, IL-4 (10 ng/ml) was added to each well, and incubated for 24 h. Cells were labeled with [³H]thymidine (1 μCi/well) for the last 6 h of incubation, and [³H]thymidine incorporation into DNA was measured by β-scintillation counting.

Results

Effect of IL-4 on cell cycle progression

Previously, we showed that IL-4 inhibited growth of all 3 human RCC cell lines, A498, CURCII and Caki-1

Table 1. Cell cycle analysis of Caki-1 cells treated with IL-4.

	Cell cycle distribution							
	G ₁ (%)		S (%)		G ₂ /M (%)		G ₁ /S ratio	
	Control	IL-4	Control	IL-4	Control	IL-4	Control	IL-4
4 h	51	53	16	14	33	33	3.19	3.79
24 h	50	70	26	17	24	13	1.92	4.12
48 h	52	70	35	16	13	14	1.49	4.38
72 h	55	74	33	13	12	13	1.67	5.69

Cells were treated with IL-4 (3 ng/ml) as described in Materials and Methods, and cell cycle was analyzed by a flow cytometry at the indicated time points. These data are the representative of 3 independent experiments.




Figure 1. Effect of IL-4 on the p21^{WAF1} expression. (A) Cells were treated with IL-4 for the indicated times at 10 ng/ml (left panel), or at the indicated concentrations for 5 h (Caki-1) or 10 h (A498) (right panel). Protein expressions of p21^{WAF1}, p27^{KIP1}, and p53 were analyzed by immunoblotting. (B) Expression levels of p21^{WAF1} mRNA were measured in Caki-1 cells by RT-PCR as described in Materials and Methods. *Indicates relative intensities of bands normalized by β-actin.

(Cheon *et al.*, 1996). To investigate the mechanism of anti-proliferative effect of IL-4, cell cycle distribution was analyzed in IL-4 treated Caki-1 cells. Four hours after IL-4 treatment, no significant changes in the cell cycle distribution were observed by flow cytometry analysis. However, at 24, 48, and 72 h, fractions of cells in the G₁ phase were increased 35-40% compared to the control (70% vs. 50% at 24 h), whereas S phase fractions were decreased 35-61% (17% vs. 26% at 24 h) (Table 1). These data showed that IL-4 blocked cell cycle progression at the G₁/S transition.

Effect of IL-4 on p21^{WAF1} expression

Since IL-4 induced G₁ cell cycle arrest, expressions of cell cycle regulatory proteins were analyzed by immunoblotting in Caki-1 cells. As shown in Figure 1A, the expression of p21^{WAF1} was elevated as early as 1 h after IL-4 treatment, whereas p27^{KIP1} expression did not change. Increased expression of the p21^{WAF1} protein was also observed in another RCC cell line, A498. Up-regulation of the p21^{WAF1} protein was transcriptional, since its mRNA level was also increased at 1 h after IL-4 treatment (Figure 1B). p53

expression was not enhanced by IL-4 indicating that the up-regulation of p21^{WAF1} was p53-independent (Figure 1A). No significant changes were observed in p16^{INK4a} and cyclin D1 protein expressions, and pRb phosphorylation (data not shown).

Effect of IL-4 on CDK2 activity

Since CDK2 activity was required for the G₁/S transition, and p21^{WAF1} was known to inhibit CDK2 activity, we analyzed CDK2 activity in Caki-1 cells treated with IL-4. After immunoprecipitation, CDK2 kinase activity was measured *in vitro* using histone H1 as a substrate. CDK2 activity was reduced by IL-4 treatment in a time- and dose-dependent manner (Figure 2A and B). After 4 h of IL-4 treatment, CDK2 activity




Figure 2. Effect of IL-4 on the CDK2 activity. Caki-1 cells were treated with IL-4 for the indicated times at 3 ng/ml (A), or at the indicated concentrations for 12 or 24 h (B). The activity of CDK2 was determined by *in vitro* kinase assay as described in Materials and Methods. The autoradiogram was analyzed by densitometry (A, lower panel).




Figure 3. Effect of the p21^{WAF1} antisense oligonucleotide on the growth suppression by IL-4. Caki-1 cells were transfected with sense (S) or antisense (AS) oligonucleotide of p21^{WAF1}, and 4 h later, treated with IL-4 (10 ng/ml). (A) Cell lysates were prepared at 4 and 8 h after IL-4 treatment, and the p21^{WAF1} expression was analyzed by immunoblotting. (B) Proliferation was measured by [³H]thymidine incorporation assay as described in Materials and Methods. Percent inhibition (%) was calculated as follows: {1-(CPM of treated cells/CPM of control cells)}×100. *Indicates P < 0.05 (Student's *t*-test). Data shown here are the representatives of 3 independent experiments.

started to decrease, and by 24 h, it was reduced to about 50% of the control level (Figure 2A). On immunoblot analysis, the protein level of CDK2 did not change by IL-4 treatment (data not shown), indicating that the increased p21^{WAF1} expression was responsible for the reduced CDK2 activity.

Effect of the p21^{WAF1} antisense oligonucleotide on IL-4-induced growth inhibition

To confirm that the increased expression of p21^{WAF1} mediated the growth suppression by IL-4, Caki-1 cells were transfected with the p21^{WAF1} antisense or sense oligonucleotide before treating with IL-4. Transfection with the p21^{WAF1} antisense, but not the sense, oligonucleotide prevented the increase of p21^{WAF1} expression by IL-4 (Figure 3A). At the same time, the p21^{WAF1} antisense oligonucleotide reversed IL-4 induced growth suppression. The effect of the p21^{WAF1} antisense oligonucleotide was dose-dependent, reaching to the maximum inhibition level at 150 nM (Figure 3B). It was noted that the IL-4-induced growth inhibition was not completely reversed by the p21^{WAF1} antisense oligonucleotide, suggesting that other

molecules were also involved in the antiproliferative effect of IL-4.

Role of IRF-1 in IL-4-induced growth inhibition of RCC cells

To search for molecules other than p21^{WAF1} that mediate the growth inhibitory effect of IL-4 in RCC cells, expressions of several growth regulatory proteins were analyzed. Among those, we found that the expression of IRF-1 protein was elevated by IL-4 treatment both in Caki-1 and A498 (Figure 4A). IRF-1 is a transcription factor with a growth inhibitory effect, and was previously shown that the expression could be modulated by IL-4 (Ohmori *et al.*, 1997; Ackermann *et al.*, 1999; Goenka *et al.*, 1999). The IRF-1 protein was up-regulated from 1 h post IL-4 treatment. The level of IRF-1 mRNA was also increased, indicating that the elevated expression of IRF-1 was transcriptional (Figure 4B). To test whether the elevation of IRF-1 expression was responsible for the growth inhibition by IL-4, the effect of the IRF-1 antisense oligonucleotide was investigated. The increase of IRF-1 expression induced by IL-4 was




Figure 4. Effect of IL-4 on the IRF-1 expression. (A) Cells were treated with IL-4 for the indicated times at 10 ng/ml (left panel), or at the indicated concentrations for 5 h (Caki-1) or 10 h (A498) (right panel). Protein expression of IRF-1 was analyzed by immunoblotting. (B) Expression level of IRF-1 mRNA was measured in Caki-1 cells by RT-PCR as described in Materials and Methods. *Indicates relative intensities of bands normalized by β-actin.




Figure 5. Effect of the IRF-1 antisense oligonucleotide on the IL-4-induced growth suppression. Caki-1 cells were transfected with sense (S) or antisense (AS) oligonucleotide of IRF-1, and 4 h later, treated with IL-4 (10 ng/ml). (A) Cell lysates were prepared at 4 h after IL-4 treatment, and the IRF-1 expression was analyzed by immunoblotting. (B) Cell proliferation was measured by [³H]thymidine incorporation assay as described in Materials and Methods. Percent inhibition (%) was calculated as follows: $\{1 - (\text{CPM of treated cells} / \text{CPM of control cells})\} \times 100$. *Indicates $P < 0.05$ (Student's *t*-test). Data shown here are the representatives of 3 independent experiments.

abrogated in cells transfected with the IRF-1 antisense oligonucleotide (Figure 5A). As shown in Figure 5B, the IRF-1 antisense oligonucleotide prevented IL-4-induced growth inhibition by 26% at 100 nM (32% in the antisense oligonucleotide treated cells vs. 43% in the sense oligonucleotide treated cells). These results show that IRF-1, in addition to p21^{WAF1}, is induced by IL-4 to suppress proliferation of the human RCC cells.

Discussion

Although almost all cell types that have been examined expressed a high affinity IL-4 receptor (Gooch *et al.*, 1998; Trejdosiewicz *et al.*, 1998), IL-4 affects growth of some cell types only. The mechanism for

a direct growth inhibitory effect in IL-4 sensitive cancer cell lines has not been extensively studied. Morisaki *et al.* (1994) reported that IL-4 regulated G1 cell cycle progression in gastric carcinoma cells by inducing hypophosphorylation of pRb, and decreasing the expressions of cyclin-D1, p34^{cdc2} and c-myc. In nontransformed B cells or astrocytes, changes in the expression level of p27^{KIP1} were observed in IL-4-induced growth modulation (Blanchard *et al.*, 1997; Liu *et al.*, 1997). However, we did not find changes in the protein expressions of cyclin D1, p34^{cdc2}, c-myc (unpublished data), or p27^{KIP1} in IL-4 treated RCC cells. In another report by Liu *et al.* (2000), p53-dependent induction of p21^{WAF1} was required for the IL-4-mediated increase of the p27^{KIP1} protein which was responsible for the growth arrest by IL-4 in low grade astrocytoma cells. Therefore, they suggested that both p21^{WAF1} and p27^{KIP1} were employed as dual inhibitors of astrocytoma cycling at the G1/S interphase. Our results are consistent with theirs in that p21^{WAF1} is a key mediator of IL-4-induced growth inhibition, although there are some discrepancies. In this study, the increase of p21^{WAF1} expression is p53-independent, and the expression of p27^{KIP1} does not change by IL-4.

The importance of p21^{WAF1} up-regulation in the IL-4-induced growth inhibition was demonstrated by using an antisense oligonucleotide that significantly reversed the effect of IL-4. However, p21^{WAF1} antisense oligonucleotide did not prevent the IL-4-induced growth suppression completely, suggesting that there were additional mechanisms responsible for the antiproliferative effect of IL-4. Our data indicate that the increased expression of IRF-1 is also responsible for the growth suppression by IL-4. However, how IRF-1 suppresses cellular growth is not known. An interesting possibility was suggested by Miyazaki *et al.* (1998) that IRF-1 activated p21^{WAF1} expression in a p53-independent pathway. Currently, this possibility is being tested in our system. According to the previous reports, IL-4 could either inhibit or induce the expression of IRF-1: IFN- γ -induced and Stat1-dependent activation of the IRF-1 promoter was inhibited by IL-4 in some cases (Ohmori *et al.*, 1997; Goenka *et al.*, 1999), whereas in another case, IL-4 was shown to enhance the expression of IRF-1 (Ackermann *et al.*, 1999). Concurrent induction of IRF-1 and p21^{WAF1} has been observed in growth inhibition of squamous cervical carcinoma cell lines by IFN- β /retinoic acid treatment (Giandomenico *et al.*, 1998). In summary, we showed here that IL-4 increased IRF-1 and p21^{WAF1} expressions *via* transcriptional activation to induce growth inhibition and G1 cell cycle arrest. To our knowledge, concurrent induction of p21^{WAF1} and IRF-1 by IL-4 has not been reported. Increased expression of p21^{WAF1} would result in the

reduction of CDK2 activity, and thereby induce G1 cell cycle arrest. Questions such as how IRF-1 suppresses cellular growth, and which signaling pathway is responsible for the transcriptional activation of p21^{WAF1} and IRF-1 need to be answered.

Acknowledgement

This work was supported by the National Nuclear R&D Program of the Ministry of Science and Technology and the Korea Science and Engineering Foundation (Grant No. M2-0104-00-0035-01-A04-00-017-3-0) and the Brain Korea 21 Project. We thank Drs. Soo Il Chung and Sangduk Kim for critical reading of the manuscript.

References

Ackermann LW, Wollenweber LA, Denning GM. IL-4 and IFN-gamma increase steady state levels of polymeric Ig receptor mRNA in human airway and intestinal epithelial cells. *J Immunol* 1999;162:5112-8

Blanchard DA, Affredou MT, Vazquez A. Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation. *J Immunol* 1997;158:3054-61

Brown MA, Hural J. Functions of IL-4 and control of its expression. *Crit Rev Immunol* 1997;17:1-32

Cheon J, Chung DJ, Kim JJ, Koh SK, Sohn J. Inhibitory effects of interleukin-4 on human renal cell carcinoma cells in vitro: in combination with interferon- α , tumor necrosis factor- α or interleukin-2. *Int J Urol* 1996;3:196-201

Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987;162:156-9

Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. *Proc Natl Acad Sci USA* 1995;92:5545-9

Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21^{CIP1/WAF1} undergo normal development, but are defective in G1 checkpoint control. *Cell* 1995;82:675-84

Eum WS, Li MZ, Sin GS, Choi SY, Park JB, Lee JY, Kwon HY. Dexamethasone-induced differentiation of pancreatic AR42J cell involves p21^{waf1/cip1} and MAP kinase pathway. *Exp Mol Med* 2003;35:379-84

Gartel AL, Tyner AL. Transcriptional regulation of the p21^{WAF1/CIP1} gene. *Exp Cell Res* 1999;246:280-9

Giandomenico V, Vaccari G, Fiorucci G, Percario Z, Vannuchi S, Matarrese P, Malorni W, Romeo G, Affabris GR. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. *Eur Cytokine Netw* 1998;9:619-31

Goenka S, Youn J, Dzurek LM, Schindler U, Yu-Lee LY,

Boothby M. Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation. *J Immunol* 1999;163:4663-72

Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. *Science* 1991;254:713-6

Gooch JL, Lee AV, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. *Cancer Res* 1998;58:4199-205

Liu J, Flanagan WM, Drazba JA, Estes ML, Barnett GH, Haqqi T, Kondo S, Barna BP. The CDK inhibitor, p27Kip1, is required for IL-4 regulation of astrocyte proliferation. *J Immunol* 1997;159:812-9

Liu J, Estes ML, Drazba JA, Liu H, Prayson R, Kondo S, Jacobs BS, Barnett GH, Barna BP. Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. *Oncogene* 2000;19:661-9

Medema RH, Klompmaker R, Smits VA, Rijksen G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. *Oncogene* 1998;16:431-41

Miyazaki M, Ohashi R, Tsuji T, Mihara K, Gohda E, Namba M. Transforming growth factor beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1. *Biochem Biophys Res Commun* 1998;246:873-80

Morisaki T, Uchiyama A, Yuzuki D, Essner R, Morton DL, Hoon DS. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. *Cancer Res* 1994;54:1113-8

Noffz G, Qin Z, Kopf M, Blankenstein T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. *J Immunol* 1998;160:345-50

Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth *in vitro* by interleukin-4. *J Clin Invest* 1993;91:88-93

Ohmori Y, Hamilton TA. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. *J Immunol* 1997;159:5474-82

Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21^{WAF1} and p27^{KIP1}, independent of p53. *Oncogene* 1998;17:2393-402

Sohn J, Lee CH, Chung DJ, Park SH, Kim I, Hwang WI. Effect of petroleum ether extract of Panax ginseng roots on proliferation and cell cycle progression of human renal cell carcinoma cells. *Exp Mol Med* 1998;30:47-51

Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. *Cell* 1994;77:829-39

Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity *in vivo*. *Cell* 1989;57:503-12

Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. *Science* 1992;257:548-51

Trejdosiewicz LK, Morton R, Yang Y, Banks RE, Selby PJ, Southgate J. Interleukins 4 and 13 upregulate expression of CD44 in human colonic epithelial cell lines. *Cytokine* 1998;10:756-65

Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka

N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. *Science* 1993; 259:968-71

Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS, van Wijnen AJ. The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. *J Biol Chem* 2003;278:26589-96